Skip to content

Avalo Therapeutics AVTX Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

Xencor logo
XencorXNCR
$741K+4.1%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$816.53M+3.3%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$29K-3.3%
Absci Corporation logo
Absci CorporationABSI
$15K+15.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$72K+12.5%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$954.59M+1,800%
Enterprise value$929.6M-1,353%
P/S1,909.2×+1,868×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%
Debt / equity0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Avalo Therapeutics (AVTX) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $25K in Q1 2026.
How has Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 127.3% year-over-year, from $11K to $25K.
What is the long-term trend for Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 5 years (2020 to 2025), Avalo Therapeutics's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a -24.8% compound annual growth rate (CAGR), from $75K to $18K.
What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.